Tom Coll

Cooley advised Wugen, a clinical-stage biotechnology company pioneering the next generation of allogeneic, off-the-shelf chimeric antigen receptor T-cell (CAR-T) therapies, on its $115 million Series C financing.

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Cooley advised Tentarix Biotherapeutics and three of its subsidiaries on three multiyear collaborations with Gilead Sciences.

Cooley advised Morphimmune, a private biotechnology company, in its definitive merger agreement with Immunome and $125 million private investment.

Cooley advised Red Tree Venture Capital on a $108 million oversubscribed Series B financing – co-led by RA Capital Management – in Bicara Therapeutics, a clinical-stage biotechnology company developing biologics for anti-tumor response.